Insights On Drug Discovery

  1. The Scalability Of Depth Filters For CHO Cell Culture Clarification 7/19/2024

    Clarification using depth filtration is standard in monoclonal antibody (mAb) manufacturing. Here, we showcase the scalability of Stax™ mAx depth filters, demonstrating their effectiveness.

  2. Leveraging The Right RNA Polymerase Enhance Capping Efficiency 6/10/2024

    By utilizing an engineered co-transcriptional capping RNA Polymerase, researchers can reduce the production of double-stranded RNA byproducts and enhance the functionality of mRNA therapeutics.

  3. Evolution Of Immunogenicity Assessment: Moving Into The Data Rich Era 5/23/2024

    Early immunogenicity risk assessment can strengthen IND applications. Review the performance of a flow cytometry-based assay that enables a more comprehensive understanding of immunogenicity risk.

  4. Immunogenicity Assessments – Frequently Asked Questions 5/20/2024

    Through a deeper understanding of immunogenicity, researchers can harness the full potential of advanced therapies, paving the way for a future of safer and more effective treatments for diseases.

  5. Next-Generation EpiScreen® Immunogenicity Assay 5/20/2024

    Assessing a drug's immunogenic potential early in development is critical for success. Review a platform that leverages a data-rich approach to provide a deeper understanding of immunogenicity risk.

  6. Compound Library Consortium 5/16/2024

    Explore how a novel approach to enhancing drug discovery efforts can significantly improve the chances of identifying promising drug candidates, ultimately accelerating the path from discovery to development.

  7. How T3P Can Enable Greener, Cost-Effective Peptide Synthesis 5/16/2024

    Read how our collaboration with the Peptide Science Laboratory Institution is transforming peptide synthesis with green chemistry, paving the way for more sustainable and cost-effective pharmaceutical production.

  8. How T3P Is Helping To Advance API Development 5/16/2024

    Uncover how innovative reagent selection accelerates the development of promising drug-like molecules in challenging research environments.

  9. Can't Afford A Head Of Clinical And CMC? Think Again 5/15/2024

    Brian James of Rondaxe, and Joanne Beck of Aerium Therapeutics, consider the basic “org chart” needed to ensure development and manufacturing success at your CDMO.

  10. How Much Do You Need To Pay Your CDMOs … And When? 5/15/2024

    Striking a balance between must-haves, and thus must-pay-fors, with the need for development speed and budgetary constraints, was a serious subject for our outsourcing professionals.